Bazedoxifene, approved by the Food and Drug Administration (FDA) as a selective estrogen modulator for osteoporosis treatment [90], has been demonstrated to be a new drug that inhibits the IL-6/gp130/STAT3 pathway [91]. The gene discussed is IL6; the disease is osteoporosis.